Andreas Wicki

6.5k citations

81 papers · 4.6k indexed · 2 hit papers · h-index 27

Impact in

Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
Oncology top 2%
- Cancer Cells and Metastasis
- Lymphatic System and Diseases
- Cancer Immunotherapy and Biomarkers

Papers in

Oncology 44
- Colorectal Cancer Treatments and Studies 9
- Cancer Treatment and Pharmacology 6
- Cancer Immunotherapy and Biomarkers 6
Gastroenterology 5

Co-authors: Jörg Huwyler Dominik Witzigmann Vimalkumar Balasubramanian Gerhard Christofori François Lehembre Kenneth J. Clemetson Brigitte Hantusch Nikolaus Wick
Journals: Journal of Clinical Oncology (5 papers)Blood (4 papers)Annals of Oncology (4 papers)Clinical Cancer Research (3 papers)International Journal of Cancer (3 papers)
Partner nations: Switzerland Germany Italy

In The Last Decade

Andreas Wicki

75 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Biology, vulnerabilities and clinical applications of circulating tumour cells 2022 · 189 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Nature reviews. Cancer
2014 Journal of Controlled Release

Peers

Countries citing papers authored by Andreas Wicki

Since Specialization

Citations

This map shows the geographic impact of Andreas Wicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Wicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Wicki more than expected).

Fields of papers citing papers by Andreas Wicki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Wicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Wicki. The network helps show where Andreas Wicki may publish in the future.

Co-authors

The 25 scholars most cited alongside Andreas Wicki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andreas Wicki Line = papers co-authored together Andreas Wicki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology European Journal of Cancer ·Damian Rieke, Michael Bitzer, Annalen Bleckmann, Alexander Desuki, Thomas Ernst, Iréne Esposito, Armin Gerger, Hanno Glimm, Peter Horak, Daniel Hübschmann, Anna Lena Illert, Volker Kunzmann, Sonja Loges, Ina Pretzell, Katja Schmitz, Andreas Seeber, Bärbel Söhlke, Andreas Wicki, Jürgen Wolf, Georg Maschmeyer	2025	0
2	Comparative inpatient care of cancer vs. non-cancer patients in Switzerland during the national COVID-19 lockdown: a nationwide interrupted time series analysis BMC Cancer ·Loïc Brunner, Anna Nicolet, Isabelle Peytremann‐Bridevaux, Joachim Marti, Jean‐Luc Bulliard, Lorenzo Righi, Christian Britschgi, Andreas Wicki, Christine Bienvenu, Ursula Ganz-Blaettler, Manuela Eicher, Olivier Michielin, Karine Moschetti, Marie‐Annick Le Pogam	2025	0
3	The molecular tumor board—a key element of precision oncology memo - Magazine of European Medical Oncology ·Laura Boos, Andreas Wicki	2024	3
4	Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study Cancer ·Vladimir Jolidon, Manuela Eicher, Isabelle Peytremann‐Bridevaux, Stefan Aebi, Sandro Anchisi, Adrienne Bettini, Yves Chalandon, Pierre‐Yves Dietrich, Michel A. Duchosal, Donat Dürr, Solange Peters, Roger von Moos, Andreas Wicki, Chantal Arditi	2024	1
5	Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers SHILAP Revista de lepidopterología ·Sylvain Pradervand, Nicolas Freundler, Benedict Gosztonyi, L. Roncoroni, Rita Achermann, TL Schwenk, G Fraipont, Jonas Garessus, Simon Haefliger, Alexander Leichtle, Michael K. Kießling, T. Mueller-Focke, Fanny S. Krebs, Vincent Zoete, Petros Tsantoulis, Olivier Michielin, Christian Britschgi, Andreas Wicki	2024	1
6	Impact of the COVID-19 Pandemic and Lockdown on Cancer Diagnoses Using Swiss Cantonal Cancer Registry Data Cancers ·Flurina Suter, Miriam Wanner, Dominik Menges, Andreas Wicki, Dimitri Korol, Sabine Rohrmann	2024	1
7	Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study International Journal of Cancer ·Max J. Rieger, Xenia Schenkel, Ivona Dedic, Tadeusz Brunn, Ralph Gnannt, Michael Hofmann, Olivier de Rougemont, Sebastian M. Stolz, Wiebke Rösler, Jan–Dirk Studt, Stefan Balabanov, Andreas Wicki, Anja Lorch, Markus G. Manz, Rahel Schwotzer	2023	8
8	431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16 Annals of Oncology ·Sara Bastian, Markus Joerger, Daniela Baertschi, Lisa Holer, Matthias Gückenberger, Wolfgang Jochum, Dieter Koeberle, Alexander Siebenhüner, Martin D. Berger, Ralph C. Winterhalder, Carlo R. Largiadèr, Melanie Löffler-Baumann, K. Mosna- Firlejczyk, Andreas Wicki, A. Fischer Maranta, R.A.F. von Moos	2022	0
9	Structure-based prediction of BRAF mutation classes using machine-learning approaches Scientific Reports ·Fanny S. Krebs, Christian Britschgi, Sylvain Pradervand, Rita Achermann, Petros Tsantoulis, Simon Haefliger, Andreas Wicki, Olivier Michielin, Vincent Zoete	2022	7
10	MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies Microsystems & Nanoengineering ·Fabienne D. Schwab, Manuel C. Scheidmann, Lauren L. Ozimski, André Kling, Lucas Armbrecht, Till Ryser, Ilona Krol, Karin Strittmatter, Bich Doan Nguyen-Sträuli, Francis Jacob, André Fedier, Viola Heinzelmann‐Schwarz, Andreas Wicki, Petra S. Dittrich, Nicola Aceto	2022	17
11	268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14] Annals of Oncology ·Andreas Wicki, Christoph Mamot, Ursula Hasler-Strub, Salomé Riniker, Q. Li, Lisa Holer, Daniela Baertschi, Khalil Zaman, Roger von Moos, Konstantin J. Dedes, Urban Novak, Alexandre Bodmer, Reto Ritschard, Ellen C. Obermann, Christoph Ackermann, V. Membrez-Antonioli, U. Zuerrer, Clemens B. Caspar, Christoph Rochlitz, Ralph C. Winterhalder	2021	4
12	Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms Laboratory Investigation ·Thibaud Koessler, Viola Paradiso, Salvatore Piscuoglio, Ronny Nienhold, Liza Ho, Yann Christinat, Luigi Terracciano, Gieri Cathomas, Andreas Wicki, Thomas McKee, Thierry Nouspikel	2020	15
13	Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front American Journal Of Pathology ·Akiko Kunita, Vanessa Baeriswyl, Claudia Meda, Erik Cabuy, Kimiko Takeshita, Enrico Giraudo, Andreas Wicki, Masashi Fukayama, Gerhard Christofori	2018	23
14	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling Physiological Reviews ·Andreas Wicki, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue	2016	49
15	Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy Journal of drug targeting ·Annette Orleth, Christoph Mamot, Christoph Rochlitz, Reto Ritschard, Kari Alitalo, Gerhard Christofori, Andreas Wicki	2015	18
16	Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors EJNMMI Research ·Andreas Wicki, Damian Wild, Vincent Prêtre, Rosalba Mansi, Annette Orleth, Jean–Claude Reubi, Christoph Rochlitz, Christoph Mamot, Helmut R. Mäcke, Gerhard Christofori	2014	4
17	Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth Clinical Cancer Research ·Andreas Wicki, Christoph Rochlitz, Annette Orleth, Reto Ritschard, Imke Albrecht, Richard Herrmann, Gerhard Christofori, Christoph Mamot	2011	77
18	NCAM‐induced focal adhesion assembly: a functional switch upon loss of E‐cadherin The EMBO Journal ·François Lehembre, M. Deniz Yilmaz, Andreas Wicki, Tibor Schomber, Karin Strittmatter, Dominik Ziegler, Angelika Kren, Phillip Went, Patrick W.B. Derksen, Anton Berns, Jos Jonkers, Gerhard Christofori	2008	156
19	Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton Cancer Cell ·Andreas Wicki, François Lehembre, Nikolaus Wick, Brigitte Hantusch, Dontscho Kerjaschki, Gerhard Christofori	2006	477
20	The potential role of podoplanin in tumour invasion British Journal of Cancer ·Andreas Wicki, Gerhard Christofori	2006	249

About Andreas Wicki

Andreas Wicki is a scholar working on Oncology, Gastroenterology, Cancer Research, Pulmonary and Respiratory Medicine and Hematology, having authored 81 papers that have together received 4.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers), Melanoma and MAPK Pathways (7 papers), Platelet Disorders and Treatments (7 papers), Cancer Treatment and Pharmacology (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). The work is most often cited by research in Biomaterials (1.1k citations), Oncology (1.5k citations), Hematology (406 citations), Cancer Research (453 citations) and Molecular Biology (1.8k citations). Andreas Wicki has collaborated with scholars based in Switzerland, Germany and Italy. Frequent co-authors include Jörg Huwyler, Dominik Witzigmann, Vimalkumar Balasubramanian, Gerhard Christofori, François Lehembre, Kenneth J. Clemetson, Brigitte Hantusch, Nikolaus Wick, Dontscho Kerjaschki and Christoph Rochlitz. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, Clinical Cancer Research and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact